Cell Therapeutics Readies Commercial Launch of Pixuvri® in EU; Re-Alignment ... Business Review India (press release) CTI is currently accruing patients into a Phase III trial comparing pixantrone and rituximab with gemcitabine and rituxan in the setting of aggressive B-cell Non-Hodgkin Lymphoma. European sites will be participating in this study later this year ... |
